705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)

Autor:	S. Mao, Arlene O. Siefker-Radtke, H. Der-Torossian, Nancy B. Davis, Roberto Pili, J. Christensen, A. Rezazadeh Kalebasty, Tian Zhang, R. Shazer, Ulka N. Vaishampayan, Pavlos Msaouel, Randy F. Sweis, S. Gandhi, X. Yan, Jonathan E. Rosenberg, L.T. Nordquist, Manojkumar Bupathi, M. Winter, G. Vasudeva Iyer, David R. Shaffer
Rok vydání:	2020
Předmět:	Metastatic Urothelial Carcinoma Oncology business.industry Immune checkpoint inhibitors Sitravatinib Cancer research Medicine Hematology Nivolumab business
Zdroj:	Annals of Oncology. 31:S556
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.777
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::19b924740c647e6e47b79a2f1edaf4f2 https://doi.org/10.1016/j.annonc.2020.08.777 Zobrazit plný text záznamu